NCT02423187
Completed
Not Applicable
Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Gastric Ulcer
- Sponsor
- Eisai Co., Ltd.
- Enrollment
- 1568
- Primary Endpoint
- Incidence of adverse drug reactions
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
To investigate the safety and efficacy of long-term combination therapy with rabeprazole and low-dose aspirin.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Incidence of adverse drug reactions
Time Frame: 52 weeks
Secondary Outcomes
- Recurrence rate of peptic ulcer(52 weeks)
Similar Trials
Completed
Phase 3
Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)Symptomatic Gastroesophageal Reflux Disease (sGERD)NCT00911534Eisai Inc.305
Unknown
Not Applicable
Rabeprazole specific clinical experience investigation for the long-term combination therapy with low-dose aspiriGastric ulcer, Duodenal ulcerJPRN-jRCT1080222833Eisai Co., Ltd.1,400
Completed
Phase 3
Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.Gastroesophageal RefluxHeartburnNCT00553449Janssen-Ortho Inc., Canada48
Completed
Phase 3
A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric PatientsGastroesophageal Reflux Disease (GERD)NCT00787891Johnson & Johnson Pharmaceutical Research & Development, L.L.C.127
Completed
Phase 2
A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)Functional DyspepsiaNCT01089543Eisai Co., Ltd.338